CSL (CSL) AI Stock Analysis

• Market Cap: $115.46B
• Dividend Yield: 1.72%
• Average Volume (3M): 699.98K
• Price to Earnings (P/E): 28.0
• Beta (1Y): 0.56
• Revenue Growth: 8.00%
• EPS Growth: 9.09%
• Country: AU
• Employees: 32,698
• Sector: Healthcare
• Sector Strength: 49
• Industry: Biotechnology
• EPS (TTM): 6.67
• Shares Outstanding: 484,212,130
• 10 Day Avg. Volume: 804,317
• 30 Day Avg. Volume: 699,981
• PEG Ratio: 0.77
• Price to Book (P/B): 13.06
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 194.32
• Enterprise Value/Market Cap: 0.63
• Enterprise Value/Revenue: 1.26
• Enterprise Value/Gross Profit: 9.82
• Enterprise Value/Ebitda: 3.92
• 1Y Price Target: $313.46
• Price Target Upside: 31.46% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8

• Rating: 69 Neutral
• Price Target: AU$269.00 ▲(12.81%Upside)

CSL's strong financial performance and positive earnings call sentiment are significant positives, reflecting stability and growth potential. However, high valuation metrics and mixed technical indicators suggest caution. The company's robust revenue growth and innovative advancements are offset by increased debt and specific challenges in certain segments.

CSL Business Overview & Revenue Model

Company Description

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and CSL Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The CSL Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.

How the Company Makes Money

CSL generates revenue primarily through the sale of its biotherapies and vaccines. The CSL Behring segment contributes significantly to the company's earnings by offering a range of plasma-derived and recombinant therapies, which are sold to healthcare providers, hospitals, and governments worldwide. The Seqirus segment enhances revenue through the production and distribution of influenza vaccines, leveraging both traditional egg-based and innovative cell-based vaccine technologies. CSL's strategic partnerships with healthcare organizations and research institutions further bolster its revenue streams, while its global operations allow for market expansion and the ability to meet diverse healthcare needs across different regions.

CSL Financial Statement Overview

Summary

CSL shows consistent revenue growth and robust profitability metrics. While balance sheet strength is evident, the increasing debt level requires monitoring. Cash flow is positive but volatile, indicating room for improvement in capital management.

Income Statement

CSL has demonstrated consistent revenue growth over the years, highlighted by a strong revenue increase from 2020 to 2023. Gross profit margins have remained robust, reflecting effective cost management. However, the EBIT margin has shown some volatility, indicating fluctuations in operational efficiency. The net profit margin is healthy, but has slightly decreased in the most recent period, suggesting increased expenses or cost pressures.

Balance Sheet

The balance sheet shows a strong equity position, with a growing stockholders' equity over the years. The debt-to-equity ratio is relatively moderate, suggesting a balanced capital structure. However, the total debt has increased significantly, which could pose potential risk if not managed properly. The equity ratio remains stable, indicating financial stability, but the rising debt warrants careful monitoring.

Cash Flow

CSL has maintained positive free cash flow, reflecting the company's ability to generate cash after capital expenditures. However, the free cash flow growth rate has been inconsistent, with notable fluctuations. The operating cash flow to net income ratio is healthy, indicating good cash generation relative to profits. The variability in free cash flow suggests potential challenges in managing capital expenditures efficiently.

Breakdown	TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	14.98B	14.69B	13.17B	10.49B	10.33B	9.41B
Gross Profit	7.36B	7.56B	6.71B	5.66B	5.80B	5.28B
EBITDA	4.98B	4.73B	3.90B	3.46B	2.72B	2.18B
Net Income	3.12B	2.64B	2.19B	2.25B	2.39B	2.17B
Balance Sheet
Total Assets	38.45B	38.02B	54.43B	41.22B	18.16B	15.46B
Cash, Cash Equivalents and Short-Term Investments	1.52B	1.66B	2.33B	15.18B	1.81B	1.19B
Total Debt	11.96B	12.18B	18.37B	14.04B	5.81B	5.99B
Total Liabilities	17.90B	18.62B	27.65B	20.02B	9.74B	8.94B
Stockholders Equity	18.56B	17.33B	23.72B	21.20B	8.38B	6.53B
Cash Flow
Free Cash Flow	1.88B	1.51B	1.35B	1.90B	1.97B	1.16B
Operating Cash Flow	1.71B	2.81B	3.87B	3.62B	3.65B	2.57B
Investing Cash Flow	-924.09M	-1.26B	-17.61B	-2.26B	-1.68B	-1.41B
Financing Cash Flow	-1.43B	-1.28B	677.92M	10.58B	-1.41B	-664.30M

CSL Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 238.45
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:CSL, the sentiment is Negative. The current price of 238.45 is below the 20-day moving average (MA) of 242.55, below the 50-day MA of 243.19, and below the 200-day MA of 266.50, indicating a bearish trend. The MACD of -1.44 indicates Positive momentum. The RSI at 41.76 is Neutral, neither overbought nor oversold. The STOCH value of 44.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:CSL.

CSL Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CSL	69 Neutral	$115.46B	28.03	15.38%	1.72%	8.00%	9.09%
Sector *	46 Neutral	C$189.51M	-4.27	-8.56%	3.09%	13.68%	-1.94%
CLVLF		$329.19M	14.14	19.93%	0.44%	―	―
MEOBF		$1.34B	―	-21.31%	―	―	―
NURPF		$1.03B	11.99	51.39%	―	―	―
PRRUF		$228.59M	―	-31.16%	―	―	―
TLPPF		$5.37B	158.13	14.52%	―	―	―

CSL Corporate Events

CSL’s ANDEMBRY® Gains FDA Approval for Hereditary Angioedema Treatment

CSL has announced the FDA approval of ANDEMBRY®, a groundbreaking treatment for hereditary angioedema (HAE), marking its immediate launch in the United States. This approval enhances CSL’s market positioning, offering the first and only prophylactic treatment targeting factor XIIa for HAE, with significant efficacy demonstrated in clinical trials. The treatment’s approval in multiple regions, including the EU and Japan, underscores its global impact and potential benefits for patients, stakeholders, and the company’s operations.

The most recent analyst rating on (AU:CSL) stock is a Buy with a A$325.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.

CSL Limited Appoints Cameron Price as Non-executive Director

CSL Limited has announced the appointment of Mr. Cameron Price as an independent Non-executive Director, effective October 1, 2025. Mr. Price brings extensive experience from his previous role as General Counsel & Chief Risk Officer at Australia’s Future Fund and his background in mergers & acquisitions and corporate governance. His appointment is expected to enhance CSL’s board with his insights and commercial acumen, potentially strengthening the company’s strategic positioning in global investment markets.

The most recent analyst rating on (AU:CSL) stock is a Buy with a A$310.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.

CSL Limited Announces Cessation of Securities

CSL Limited announced the cessation of 8,790 securities due to the lapse of conditional rights, as the conditions were not met or became incapable of being satisfied. This cessation reflects a specific adjustment in the company’s issued capital, potentially impacting shareholder value and market perception of the company’s securities management.

The most recent analyst rating on (AU:CSL) stock is a Buy with a A$310.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.

CSL Limited Announces Cessation of Securities

CSL Limited announced the cessation of 12,039 securities due to the lapse of conditional rights, as the conditions were not met or became incapable of being satisfied. This development may impact the company’s capital structure and could have implications for stakeholders regarding the company’s strategic financial management.

CSL Limited Announces Cessation of Securities

CSL Limited announced the cessation of 6,106 conditional rights to securities as the conditions for these rights were not met or became incapable of being satisfied. This announcement may impact CSL’s capital structure and could have implications for stakeholders regarding the company’s financial strategies and market operations.

CSL Monitors U.S. Tariff Developments to Safeguard Medicine Access

CSL has responded to the recent announcement by the United States Administration regarding the imposition of reciprocal tariffs on imports. While pharmaceutical products are currently exempt from these tariffs, CSL is closely monitoring the situation to assess any broader impacts. The company is committed to collaborating with the U.S. administration to ensure that American patients continue to have access to its lifesaving medicines.